Rudenko V I, Rapoport L M, Demidko Yu L, Demidko L S, Inoyatov G S, Allenov S N
Institute of Urology and Reproductive Health of FGAOU VO I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia, Moscow, Russia.
Urologiia. 2019 Jul(3):43-49.
Rowatinex is a combined drug based on plant terpenes which provides diuretic, anti-inflammatory and antispasmodic effect. A use of herbal preparation Rowatinex in patients with urinary stone disease after extracorporeal shock-wave therapy (ESWL) is analyzed in the article.
To clarify the efficiency of the drug Rowatinex in patients with urinary stone disease after ESWL.
All patients were divided into two groups depending on therapy administered after ESWL. In main group (n=150) patients received Rowatinex, while in control group (n=70), antispasmodics were administered. Spontaneous passage of fragments was observed in 104 patients in main group (69.3%) and 30 patients in control group (42.9%).
When studying the effect of therapy on the changes of complete blood count, biochemical panel and daily excretion of some substances (magnesium, uric acid, calcium, etc) there were no significant differences between main group and control group. All values were normal. It was estimated that increase in diuresis during use of Rowatinex contributes to effective and rapid passage of stone fragments. In addition, there was a decrease in leukocyturia in both groups.
Drug Rowatinex allows to reduce the time to spontaneous passage of fragments after ESWL, intensity of pain syndrome and leukocyturia as well as to increase in daily diuresis. This is not accompanied by the development of complications and side effects which allows to administer Rowatinex for a long time as part of complex medical expulsive therapy and use it for recurrence prevention of urinary stone disease. Effect of Rowatinex didnt depend on the stone composition.
Rowatinex是一种基于植物萜烯的复方药物，具有利尿、抗炎和解痉作用。本文分析了草药制剂Rowatinex在体外冲击波碎石术（ESWL）后尿路结石病患者中的应用。
明确Rowatinex药物在ESWL后尿路结石病患者中的疗效。
根据ESWL后给予的治疗方法，将所有患者分为两组。主要组（n = 150）患者接受Rowatinex治疗，而对照组（n = 70）给予解痉药。主要组104例患者（69.3%）和对照组30例患者（42.9%）观察到结石碎片自然排出。
在研究治疗对全血细胞计数、生化指标和某些物质（镁、尿酸、钙等）每日排泄量变化的影响时，主要组和对照组之间没有显著差异。所有值均正常。据估计，使用Rowatinex期间利尿增加有助于结石碎片有效快速排出。此外，两组白细胞尿均减少。
Rowatinex药物可减少ESWL后结石碎片自然排出的时间、疼痛综合征强度和白细胞尿，并增加每日尿量。这不会伴随并发症和副作用的发生，这使得Rowatinex可以作为复杂药物排石治疗的一部分长期使用，并用于预防尿路结石病的复发。Rowatinex的效果不取决于结石成分。
